📌 At a Glance
- Revenue from Operations: ₹3,885.6 Cr
- Other Income: ₹30.2 Cr
- Total Income: ₹3,915.8 Cr
- Net Profit: ₹209 Cr
- EPS: ₹35.86
- Tax Paid: ₹75.8 Cr
- Debt-to-Equity: Just 0.0008 🤏
- DSCR: 0.0069 😬
- ISCR: 0.1672 😅
👉 Translation: Balance sheet = Yoga guru. Cash flows = Gym dropout.
🧬 About the Company
Ajanta Pharma Ltd is a Mumbai-based pharmaceutical company that produces, markets, and exports generics and branded formulations in over 30 countries. Its portfolio spans dermatology, ophthalmology, cardiology, and pain management.
They don’t chase trends like GLP-1 or AI. They just quietly mint money like your neighbourhood chemist who always has “stock hai bhai, generic bhi milega.”
🧑⚖️ Key Managerial Personnel (FY25)
| Name | Designation |
|---|---|
| Yogesh M. Agrawal | Managing Director |
| Rajesh S. Agrawal | Joint Managing Director |
| Kalpesh A. Agrawal | Director |
| Anil Agrawal | Whole-Time Director |
| Nilesh Shah | Independent Director |
| Poonam Agarwal | Independent Director |
Family business? More like Agrawal Pharma Ltd.
💰 Financials (FY25 Standalone)
| Particulars | Amount (₹ Cr) |
|---|---|
| Revenue from Operations | 3,885.6 |
| Other Income | 30.2 |
| Total Income | 3,915.8 |
| Raw Material Cost | 2,635.6 |
| Change in Inventory | -951.4 |
| Employee Cost | 693.2 |
| Finance Cost | 40.5 |
| Depreciation | 182.6 |
| Other Expenses | 939.5 |
| Total Expenses | 3,548.4 |
| PBT | 367.4 |
| Tax | 75.8 |
| PAT | 209 |
| EPS (Basic & Diluted) | ₹35.86 |
➡️ Boring but efficient. Like your dad’s investment in PPF.
🧮 Forward-Looking Fair Value (FV) Estimate
Let’s apply some industry logic and a dash of madness:
- TTM EPS = ₹35.86
- Target P/E (Conservative): 22x (Generic Pharma Avg)
- Fair Value = ₹35.86 × 22 = ₹789
CMP Check: ₹1,775 (from Trendlyne, May 19, 2025)
So Ajanta is already priced like a Harvard graduate in a village interview — way above market averages.
Implied P/E: 49.5x
💬 “Arey bhai, long-term compounding hai. Chill.”
🌱 Growth & Outlook
- 📉 FY25 revenue growth is modest.
- ✅ Steady EPS. No volatility = sleep well stock.
- 🧴 Dermatology & Cardiac therapies continue to drive revenue.
- 🌍 Exports to Africa & Asia still form >70% of revenue.
- 🧪 No big R&D bets, they play it safe.
- 💸 Minimal debt. But also… minimal excitement.
🧠 EduInvesting Take
Ajanta Pharma is that disciplined topper who never fails but also never goes viral.
- Not a 10x rocket.
- But a 2x in 5 years kinda story if you’re patient and anti-FOMO.
It’s one of those rare pharma companies where nothing is broken — but nothing is sexy either.
🚩 Risks & Red Flags
- 😐 Zero diversification in buzzword areas like biosimilars, GLP-1s, AI drug discovery.
- 💊 Margin pressure due to API inflation.
- 🌍 High dependence on exports (geopolitical risks, currency hit).
- 🐌 No acquisition or inorganic growth story.
🏁 Final Verdict
“Ajanta Pharma is like khichdi. You won’t crave it, but it won’t kill you either.”
Solid balance sheet. Fair growth. High valuation.
If you’re in your 40s, diabetic, and love fixed deposits — this might be your dream stock.
Tags: ajanta pharma share price, ajanta pharma results FY25, best pharma stocks 2025, EPS 35.86, Ajanta Pharma valuation, safe pharma bets India, eduinvesting pharma
